Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16 X Zhang, VM Crowley, TG Wucherpfennig, MM Dix, BF Cravatt Nature chemical biology 15 (7), 737-746, 2019 | 395 | 2019 |
An activity-guided map of electrophile-cysteine interactions in primary human T cells EV Vinogradova, X Zhang, D Remillard, DC Lazar, RM Suciu, Y Wang, ... Cell 182 (4), 1009-1026. e29, 2020 | 268 | 2020 |
A proteome-wide atlas of lysine-reactive chemistry ME Abbasov, ME Kavanagh, TA Ichu, MR Lazear, Y Tao, VM Crowley, ... Nature chemistry 13 (11), 1081-1092, 2021 | 170 | 2021 |
DCAF11 supports targeted protein degradation by electrophilic proteolysis-targeting chimeras X Zhang, LM Luukkonen, CL Eissler, VM Crowley, Y Yamashita, ... Journal of the American Chemical Society 143 (13), 5141-5149, 2021 | 137 | 2021 |
Natural product inspired N‐terminal Hsp90 inhibitors: from bench to bedside? A Khandelwal, VM Crowley, BSJ Blagg Medicinal research reviews 36 (1), 92-118, 2016 | 110 | 2016 |
Development of glucose regulated protein 94-selective inhibitors based on the BnIm and radamide scaffold VM Crowley, A Khandelwal, S Mishra, AR Stothert, DJE Huard, J Zhao, ... Journal of medicinal chemistry 59 (7), 3471-3488, 2016 | 87 | 2016 |
The proteome‐wide potential for reversible covalency at cysteine K Senkane, EV Vinogradova, RM Suciu, VM Crowley, BW Zaro, ... Angewandte Chemie 131 (33), 11507-11511, 2019 | 55 | 2019 |
Second generation Grp94‐selective inhibitors provide opportunities for the inhibition of metastatic cancer VM Crowley, DJE Huard, RL Lieberman, BSJ Blagg Chemistry–A European Journal 23 (62), 15775-15782, 2017 | 47 | 2017 |
Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma AR Stothert, A Suntharalingam, DJE Huard, SN Fontaine, VM Crowley, ... Human Molecular Genetics 23 (24), 6470-6480, 2014 | 47 | 2014 |
Structure based design of a Grp94-selective inhibitor: exploiting a key residue in Grp94 to optimize paralog-selective binding NLS Que, VM Crowley, AS Duerfeldt, J Zhao, CN Kent, BSJ Blagg, ... Journal of medicinal chemistry 61 (7), 2793-2805, 2018 | 40 | 2018 |
Resorcinol-based Grp94-selective inhibitors A Khandelwal, VM Crowley, BSJ Blagg ACS Medicinal Chemistry Letters 8 (10), 1013-1018, 2017 | 40 | 2017 |
Functionalized scout fragments for site-specific covalent ligand discovery and optimization VM Crowley, M Thielert, BF Cravatt ACS central science 7 (4), 613-623, 2021 | 38 | 2021 |
Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma AR Stothert, A Suntharalingam, X Tang, VM Crowley, SJ Mishra, ... Scientific Reports 7 (1), 17951, 2017 | 36 | 2017 |
Development of radamide analogs as Grp94 inhibitors A Muth, V Crowley, A Khandelwal, S Mishra, J Zhao, J Hall, BSJ Blagg Bioorganic & medicinal chemistry 22 (15), 4083-4098, 2014 | 34 | 2014 |
Trifunctional high-throughput screen identifies promising scaffold to inhibit Grp94 and treat myocilin-associated glaucoma. DJ Huard, VM Crowley, Y Du, RA Cordova, Z Sun, MO Tomlin, CA Dickey, ... ACS chemical biology, 2018 | 24 | 2018 |
Chemical proteomic identification of functional cysteines with atypical electrophile reactivities K Litwin, VM Crowley, RM Suciu, DL Boger, BF Cravatt Tetrahedron letters 67, 152861, 2021 | 10 | 2021 |
Elucidation of novel trap1-selective inhibitors that regulate mitochondrial processes T Merfeld, S Peng, BM Keegan, VM Crowley, CM Brackett, A Gutierrez, ... European journal of medicinal chemistry 258, 115531, 2023 | 8 | 2023 |
Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer NH Eisa, VM Crowley, A Elahi, VK Kommalapati, MA Serwetnyk, T Llbiyi, ... Iscience 26 (12), 2023 | 5 | 2023 |
An Efficient Synthesis of 4 (5)-Benzyl-L-histidines Employing Catalytic Transfer Hydrogenolysis at Elevated Temperatures DD Smith, AT Gallagher, VM Crowley, WM Gergens, PW Abel, M Hulce Synthesis 46 (04), 515-521, 2014 | 5 | 2014 |
Second generation GRP94-selective inhibitors BSJ Blagg, VM Crowley US Patent 11,028,041, 2021 | 3 | 2021 |